Evarex Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 03-12-2024
- Paid Up Capital ₹ 2.03 M
as on 03-12-2024
- Company Age 14 Year,
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.22 Cr
as on 03-12-2024
- Revenue -21.19%
(FY 2022)
- Profit 1.30%
(FY 2022)
- Ebitda -104.11%
(FY 2022)
- Net Worth 1.42%
(FY 2022)
- Total Assets 4.90%
(FY 2022)
About Evarex Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 2.03 M.
The company currently has active open charges totaling ₹2.22 Cr.
Sunita Tiwari, Vijay Juyal, Sunita Juyal, and Five other members serve as directors at the Company.
- CIN/LLPIN
U51101UR2011PTC033386
- Company No.
033386
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Jan 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Dehradun, Uttarakhand, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Evarex Pharmaceuticals Private Limited offer?
Evarex Pharmaceuticals Private Limited offers a wide range of products and services, including Antipyretic Medication, Paracetamol Tablets, Toothpastes, Dentassure Toothpaste, Healthcare Products & Aids, Health Drinks, Cabinet Handles, Stainless Steel D Handle, Allopathic Cough Syrup, Ambroxol Hydrochloride Syrup.
Who are the key members and board of directors at Evarex Pharmaceuticals?
Board Members(8)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunita Tiwari  | Director | 18-Jan-2011 | Current |
| Vijay Juyal | Director | 18-Jan-2011 | Current |
| Sunita Juyal | Director | 01-Mar-2013 | Current |
| Arun Tiwari | Director | 01-Mar-2013 | Current |
| Dinesh Sati | Director | 01-Mar-2013 | Current |
| Pratibha Sati | Director | 01-Mar-2013 | Current |
Financial Performance of Evarex Pharmaceuticals.
Evarex Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 21.19% decrease. The company also saw a slight improvement in profitability, with a 1.3% increase in profit. The company's net worth moved up by a moderate rise of 1.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Evarex Pharmaceuticals?
In 2020, Evarex Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 20 Jun 2020 | ₹0.50 M | Open |
Canara Bank Creation Date: 20 Jun 2020 | ₹0.50 M | Open |
Canara Bank Creation Date: 30 Dec 2017 | ₹1.85 Cr | Open |
How Many Employees Work at Evarex Pharmaceuticals?
Evarex Pharmaceuticals has a workforce of 11 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Evarex Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Evarex Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
